691 related articles for article (PubMed ID: 9216712)
1. Immunocytochemical detection of prostate specific antigen expression in human primary and metastatic melanomas.
Bodey B; Bodey B; Kaiser HE
Anticancer Res; 1997; 17(3C):2343-6. PubMed ID: 9216712
[TBL] [Abstract][Full Text] [Related]
2. Immunocytochemical detection of prostate specific antigen expression in human breast carcinoma cells.
Bodey B; Bodey B; Kaiser HE
Anticancer Res; 1997; 17(4A):2577-81. PubMed ID: 9252683
[TBL] [Abstract][Full Text] [Related]
3. Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas.
Bodey B; Bodey B; Gröger AM; Luck JV; Siegel SE; Taylor CR; Kaiser HE
Anticancer Res; 1997; 17(2B):1319-30. PubMed ID: 9137492
[TBL] [Abstract][Full Text] [Related]
4. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
5. Fas (Apo-1, CD95) receptor expression in childhood astrocytomas. Is it a marker of the major apoptotic pathway or a signaling receptor for immune escape of neoplastic cells?
Bodey B; Bodey B; Siegel SE; Kaiser HE
In Vivo; 1999; 13(4):357-73. PubMed ID: 10586378
[TBL] [Abstract][Full Text] [Related]
6. Fas (APO-1, CD95) receptor expression and new options for immunotherapy in childhood medulloblastomas.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1999; 19(4B):3293-314. PubMed ID: 10652626
[TBL] [Abstract][Full Text] [Related]
7. Nm23/nucleoside diphosphate (NDP) kinase expression in human malignant melanomas: significance and implications in tumor biology.
Bodey B; Bodey B; Gröger AM; Siegel SE; Kaiser HE
Anticancer Res; 1997; 17(1A):505-11. PubMed ID: 9066703
[TBL] [Abstract][Full Text] [Related]
8. Immunophenotypically varied cell subpopulations in primary and metastatic human melanomas. Monoclonal antibodies for diagnosis, detection of neoplastic progression and receptor directed immunotherapy.
Bodey B; Kaiser HE; Goldfarb RH
Anticancer Res; 1996; 16(1):517-31. PubMed ID: 8615665
[TBL] [Abstract][Full Text] [Related]
9. Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, nonspecific cross-reacting antigen, beta-chorionic gonadotrophin, and prostate-specific antigen.
Purnell DM; Heatfield BM; Trump BF
Cancer Res; 1984 Jan; 44(1):285-92. PubMed ID: 6197163
[TBL] [Abstract][Full Text] [Related]
10. Antibody immunoglobulin G (IgG) against human prostatic specific antigen (PSA) as a carrier protein for chemotherapeutic drugs to human prostate tumors: Part 1. A double immunofluorescence analysis.
Sinha AA; Sackrison JL; DeLeon OF; Wilson MJ; Gleason DF
Anat Rec; 1996 Aug; 245(4):652-61. PubMed ID: 8837723
[TBL] [Abstract][Full Text] [Related]
11. The role of apoptosis in normal ontogenesis and solid human neoplasms.
Kaiser HE; Bodey B
In Vivo; 2000; 14(6):789-803. PubMed ID: 11204498
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical localization of prostate-specific antigen in benign and malignant breast conditions.
Nariţa D; Raica M; Anghel A; Suciu C; Cîmpean A
Rom J Morphol Embryol; 2005; 46(1):41-5. PubMed ID: 16286983
[TBL] [Abstract][Full Text] [Related]
13. Polyclonal anti-PSA is more sensitive but less specific than monoclonal anti-PSA: Implications for diagnostic prostatic pathology.
Varma M; Morgan M; Jasani B; Tamboli P; Amin MB
Am J Clin Pathol; 2002 Aug; 118(2):202-7. PubMed ID: 12162678
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical detection of p53 protein overexpression in primary human osteosarcomas.
Bodey B; Gröger AM; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1997; 17(1A):493-8. PubMed ID: 9066701
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of growth hormone receptor immunoreactivity in human melanoma.
Lincoln DT; Sinowatz F; Kölle S; Takahashi H; Parsons P; Waters M
Anticancer Res; 1999; 19(3A):1919-31. PubMed ID: 10470136
[TBL] [Abstract][Full Text] [Related]
16. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.
Rubin MA; Mucci NR; Figurski J; Fecko A; Pienta KJ; Day ML
Hum Pathol; 2001 Jul; 32(7):690-7. PubMed ID: 11486167
[TBL] [Abstract][Full Text] [Related]
17. MAGE-1, a cancer/testis-antigen, expression in childhood astrocytomas as an indicator of tumor progression.
Bodey B; Siegel SE; Kaiser HE
In Vivo; 2002; 16(6):583-8. PubMed ID: 12494904
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical localization of prostate carcinoma-associated antigens.
Wright GL; Beckett ML; Starling JJ; Schellhammer PF; Sieg SM; Ladaga LE; Poleskic S
Cancer Res; 1983 Nov; 43(11):5509-16. PubMed ID: 6193873
[TBL] [Abstract][Full Text] [Related]
19. Immunophenotypic characterization of human primary and metastatic melanoma infiltrating leukocytes.
Bodey B; Bodey B; Siegel SE; Luck JV; Kaiser HE
Anticancer Res; 1996; 16(6B):3439-46. PubMed ID: 9042204
[TBL] [Abstract][Full Text] [Related]
20. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer.
Gomella LG; Raj GV; Moreno JG
J Urol; 1997 Aug; 158(2):326-37. PubMed ID: 9224297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
